Revance Therapeutics Inc [NASDAQ: RVNC] RVNC : Summary for Revance Therapeutics, Inc. - Yahoo Finance Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference | Revance Therapeutics, Inc. · Revance’s long-acting neuromodulator RT002, along with its unique proprietary peptide and formulation technology, will be featured in 11 podium and poster presentations at the TOXINS 2019 conference in Denmark - Revance Announces Proposed Public Offering of Common Stock Revance Announces Proposed Public Offering of Common Stock | Revance Therapeutics, Inc. NEWARK, Calif.--(BUSINESS WIRE)--Jan. 15, 2019-- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering in which it will issue and sell approximately $100 million of shares of its common stock. Revance expects that the underwriters will be granted a 30-day option to purchase from the Company up to an additional 15% of the shares of its common stock. The Company intends to use the net proceeds received from its offering of common stock for working capital and general corporate purposes, including clinical trial and related expenses, research and development expenses, general and administrative expenses, and capital investments. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC, Cowen and Piper Jaffray are acting as book-running managers for the proposed offering.